Another two-stage, two-cohort, open-label Phase 2 trial, NCT05183204, is currently recruiting to evaluate the safety and effects of the treatment with paxalisib, a new blood–brain penetrant PI3K/mTOR inhibitor, and metformin during KD in patients with newly diagnosed GBM. This evidence concerns the gene MTOR and glioblastoma.